Faculty of Medicine, University of New South Wales, Sydney, Australia.
The University of Sydney, Brain and Mind Centre and School of Psychology, Sydney, Australia; Australian Research Council Centre of Excellence in Cognition and its Disorders, Sydney, Australia.
J Neurol Sci. 2019 Jul 15;402:74-80. doi: 10.1016/j.jns.2019.04.019. Epub 2019 Apr 16.
Approximately 30% of Alzheimer's disease (AD) patients are misdiagnosed due to overlapping and evolving clinical features. In particular, the distinction of AD from behavioural variant frontotemporal dementia (bvFTD) can be challenging. Measures of visuospatial ability, which rely on parietal lobe function, show promise as markers of AD as the parietal lobe is preferentially affected early in the disease course. We hypothesise that traditional measures of visuospatial function may help distinguish AD from bvFTD.
MATERIALS & METHODS: The Addenbrooke's Cognitive Examination (ACE) visuospatial subtask, Rey-Osterrieth Complex Figure (RCF) task, and subtests of the visual object and space perception battery (VOSP) were used to examine visuospatial abilities in 55 AD patients, 51 bvFTD patients, and 54 healthy Controls. A subgroup analysis was performed in patients with Pittsburgh Compound B positron emission tomography (PiB-PET) data.
Relative to Controls, AD and bvFTD patients were impaired on almost all visuospatial tasks. Significantly worse performance was observed in AD relative to bvFTD patients on drawing tasks (ACE pentagons/loops copy, cube copy, and all RCF scores) and tasks of spatial orientation (VOSP cube analysis), when controlling for disease severity.
Visuospatial measures demonstrate limited ability to distinguish between AD and bvFTD unless disease severity is taken into consideration. Controlling for disease severity reveals a disproportionate visuospatial impairment in AD compared to bvFTD. Development of targeted measures of visuospatial function is required to improve differential diagnosis of these syndromes.
由于重叠和不断演变的临床特征,约 30%的阿尔茨海默病(AD)患者被误诊。特别是,AD 与行为变异额颞叶痴呆(bvFTD)的区分具有挑战性。依赖顶叶功能的视空间能力测量作为 AD 的标志物具有很大的潜力,因为在疾病早期,顶叶就会受到优先影响。我们假设传统的视空间功能测量可能有助于区分 AD 和 bvFTD。
使用 Addenbrooke's 认知测验(ACE)视空间子任务、Rey-Osterrieth 复杂图形(RCF)任务以及视觉物体和空间感知测验(VOSP)的子测验来检查 55 例 AD 患者、51 例 bvFTD 患者和 54 例健康对照者的视空间能力。对有匹兹堡化合物 B 正电子发射断层扫描(PiB-PET)数据的患者进行了亚组分析。
与对照组相比,AD 和 bvFTD 患者在几乎所有视空间任务上都存在障碍。在控制疾病严重程度的情况下,AD 患者在绘图任务(ACE 五边形/环复制、立方体复制和所有 RCF 评分)和空间定向任务(VOSP 立方体分析)上的表现明显差于 bvFTD 患者。
视空间测量对视空间测量在区分 AD 和 bvFTD 方面的能力有限,除非考虑到疾病严重程度。控制疾病严重程度显示,AD 患者的视空间损伤比 bvFTD 患者更为明显。需要开发针对视空间功能的靶向测量方法,以提高这些综合征的鉴别诊断能力。